So, if you see any that named me as a speaker, this is without my consent / knowledge. I would advise against registering for it. I would also advise my fellow colleagues, especially those in academia, to be vigilant on potential misuse of their names. Thank you.

<50% EEs reported intervals,diagnostic method, treatment & screening locations. None reported all aspects of screening designs.

We recommend future EEs of T2DM screening to report all aspects of screening designs, to allow synthesis and assessment of findings transferability.

Limitations:

(1) These observations are generalisations of multiple screening designs e.g., screening programme of different screening intervals, screening locations, etc.

(2) Some comparisons were contributed by single EEs.

Compared to universal screening, targeted screening (e.g., among obese) may be cost-effectv or dominant.

Similarly for expanding screening locations, or ⬇️FPG / HbA1c thresholds (but not too ⬇️) for diagnosis.

Compared to no screening,
(a) screening with biomarkers not cost-effective in ~half EEs (23/54 comparisons),
(b) screening with risk score alone mostly dominant (6/10),
(c) screening with combinations of risk score and biomarkers cost-effectv (21/40) or dominant (19/40).

We identified T2DM screening designs based on the
(a) screening tool (single biomarker, multiple biomarkers, risk scores or combinations),
(b) screening intervals,
(c) minimum age for screening,
(d) location,
(e) diagnosis method and
(f) treatment